Paul Miller
Impact in
- Biotechnology top 1%
- Cancer Research and Treatments
- Molecular Medicine top 5%
Papers in
-
- Gut microbiota and health 2
- CRISPR and Genetic Engineering 2
-
- Tuberculosis Research and Epidemiology 2
- Co-authors
- Kip A. West (5 shared papers)José M. Lora (5 shared papers)Anna Sokolovska (4 shared papers)Caroline Kurtz (4 shared papers)Laura Gambino (1 shared paper)Mark C. Sulavik (1 shared paper)Adam Fisher (4 shared papers)Ning Li (3 shared papers)
- Journals
- Gastroenterology (2 papers)Molecular Medicine (2 papers)Cancer Research (2 papers)Nature Communications (1 paper)Clinical and Translational Science (1 paper)
- Partner nations
- United States
In The Last Decade
Paul Miller
13 papers receiving 1.7k citations
Paul Miller's Hit Papers
Peers
Comparison fields: 5 of 106
- Biotechnology 419
- Molecular Medicine 122
- Infectious Diseases 302
- Molecular Biology 941
- Endocrinology 67
Countries citing papers authored by Paul Miller
This map shows the geographic impact of Paul Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Miller more than expected).
Fields of papers citing papers by Paul Miller
This network shows the impact of papers produced by Paul Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Miller. The network helps show where Paul Miller may publish in the future.
Co-authors
The 25 scholars most cited alongside Paul Miller, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria Hit paper breakdown → | 2018 | 418 |
| 2 | Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity Hit paper breakdown → | 2020 | 344 |
| 3 | An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans Hit paper breakdown → | 2019 | 290 |
| 4 | Engineering living therapeutics with synthetic biology Hit paper breakdown → | 2021 | 223 |
| 5 | 1995 | 143 | |
| 6 | 1987 | 136 | |
| 7 | 2010 | 82 | |
| 8 | 2012 | 56 | |
| 9 | 2017 | 32 | |
| 10 | 2018 | 5 | |
| 11 | 2018 | 2 | |
| 12 | 2003 | 1 | |
| 13 | 2018 | 1 | |
| 14 | 2017 | 1 | |
| 15 | 2024 | 0 |
About Paul Miller
Paul Miller is a scholar working on Molecular Biology, Infectious Diseases, Clinical Biochemistry, Physiology and Biotechnology, having authored 15 papers that have together received 1.7k indexed citations. Recurring topics across this work include Metabolism and Genetic Disorders (3 papers), Cancer Research and Treatments (3 papers), Antibiotic Resistance in Bacteria (2 papers), Tuberculosis Research and Epidemiology (2 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers), Gut microbiota and health (2 papers), Probiotics and Fermented Foods (2 papers) and CRISPR and Genetic Engineering (2 papers). The work is most often cited by research in Biotechnology (419 citations), Molecular Medicine (122 citations), Infectious Diseases (302 citations), Molecular Biology (941 citations) and Endocrinology (67 citations). Paul Miller has collaborated with scholars based in United States. Frequent co-authors include Kip A. West, José M. Lora, Anna Sokolovska, Caroline Kurtz, Laura Gambino, Mark C. Sulavik, Adam Fisher, Ning Li, Munira Momin and Yves Millet. Their work appears in journals such as Gastroenterology, Molecular Medicine, Cancer Research, Nature Communications and Clinical and Translational Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.